Arena Pharmaceuticals Announces FDA Acceptance Of Lorcaserin NDA For Filing
Friday, February 26th, 2010We recommend: buy diflucan uk, buy nolvadex uk, buy testosterone uk
Also Included In: Regulatory Affairs / Drug Approvals ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry
e-mail to a acquaintance pressman favorable aspect / publish opinions
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) proclaimed that its New Drug Application (NDA) for lorcaserin, Arena’s internally observed and highly-developed dose campaigner for burthen direction, including angle expiration and care of weightiness passing, has been recognized for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to hear the Prescription Drug User Fee Act (PDUFA) appointment in the adjacent few weeks. The PDUFA see is the butt see for the FDA to dispatch its followup of an NDA.
